Seizure Management & Medical Interventions
At a Glance
Seizure care in CNTNAP2-related DEE is individualized: anti-seizure medicine is usually first, while rescue plans, emergency assessment, a ketogenic diet, vagus nerve stimulation, or surgery may be considered when seizures remain uncontrolled.
Managing seizures in CNTNAP2-related DEE requires a proactive, individualized approach. Because the underlying genetic cause affects how the brain’s “brakes” are positioned, the brain is prone to overactivity [1]. While there is no “one-size-fits-all” medication for this condition, understanding the tools available—and the signs of an emergency—is the foundation of your child’s medical care.
Anti-Seizure Medications (ASMs)
The first line of treatment is typically medication. The goal is to reduce seizure frequency and intensity while minimizing side effects that could interfere with learning and development [2].
- Variable Response: Some studies show that about two-thirds of children may achieve good seizure control with standard medications [3]. However, others develop pharmacoresistant epilepsy, where seizures continue despite trying multiple medications [4].
- Commonly Used Drugs: Doctors often use medications standard for focal epilepsy. Your team will monitor for side effects like irritability (common with levetiracetam), cognitive “dulling” or language issues (sometimes seen with topiramate), or general sleepiness [2][5]. Importantly, anti-seizure medications must never be stopped abruptly, as this can trigger severe withdrawal seizures.
- Symptomatic Treatment: Currently, there are no gene-specific “precision” drugs for this condition. Treatment focuses on managing the symptoms as they appear [6].
Emergency Red Flags: Status Epilepticus
An epilepsy emergency, known as status epilepticus, occurs when a seizure lasts too long or when multiple seizures happen so close together that the child does not fully recover in between [7]. Every caregiver should have a written Seizure Action Plan. Basic seizure first aid includes: 1) Time the seizure. 2) Protect from injury. 3) Place the child on their side when convulsions subside. 4) Do not restrain or put anything in their mouth. 5) Do not give oral medication while unresponsive. 6) Follow the prescribed rescue-medication plan.
| Type | What it Looks Like | Action Required |
|---|---|---|
| Convulsive Status | Continuous “grand mal” shaking or stiffening [8]. | Follow your Seizure Action Plan. Administer rescue medication (like midazolam or diazepam) at the pre-set time (often 5 minutes) [9]. |
| Non-Convulsive Status (NCSE) | A “mental fog” that doesn’t lift. Your child may seem unusually confused, lethargic, or “not there” for a prolonged period [10]. | This is harder to spot. If there is new or prolonged altered awareness, a failure to return toward baseline, or an acute deterioration in responsiveness, seek emergency assessment, as NCSE is diagnosed and managed urgently with EEG monitoring [11]. |
When to Call 911/Emergency Services:
- A convulsive seizure lasts longer than 5 minutes (or as specified in your plan).
- A second seizure starts before the child has fully recovered from the first.
- The child has difficulty breathing or changes color during or after the seizure.
- The seizure occurs in water (like a bathtub or pool).
The Role and Limits of Surgery
In some forms of focal epilepsy, surgeons can remove the specific “misfiring” part of the brain to stop seizures. While children with CNTNAP2-related DEE may be less likely to have a single resectable focus due to bilateral or broader network involvement [12], they should still be evaluated at a comprehensive epilepsy center [4].
- Bilateral Involvement: Even if an MRI shows an abnormality in one temporal lobe, the genetic nature of the condition means the entire brain network is affected. Seizures often start independently in both the left and right temporal lobes [4].
- Surgical Options: Depending on the individual’s EEG, MRI, and seizure network, specialists may consider resection, ablation, or palliative procedures, although reports have shown that even when surgeons remove a visible area of cortical dysplasia, the seizures often return because the “misfiring” network is more widespread than what can be seen on a scan [12][13].
Beyond Medications: Other Interventions
If medications are not providing enough control, your team may discuss other medical interventions used in complex DEEs:
- Ketogenic Diet: A specialized, high-fat medical diet that can help stabilize brain activity in some children with drug-resistant epilepsy. It requires strict medical screening and supervision by an epilepsy dietitian [14].
- Vagus Nerve Stimulation (VNS): A small device implanted under the skin that sends regular electrical pulses to the brain to help dampen seizure activity [15].
- Routine Monitoring: It is vital to track not just seizures, but also developmental progress and medication side effects. Changes in sleep, appetite, or mood should be shared with your neurologist, as these impacts on quality of life are just as important as the seizure count itself [16][2].
Common questions in this guide
What treatments are used for seizures in CNTNAP2-related DEE?
When should I give rescue medicine or call emergency services for a seizure?
How can I recognize non-convulsive status epilepticus?
Can epilepsy surgery help a child with CNTNAP2-related DEE?
When might a ketogenic diet or VNS be considered?
Should anti-seizure medicine ever be stopped suddenly?
What should a seizure action plan and seizure log include?
Get notified when new evidence is published on CNTNAP2-related developmental and epileptic encephalopathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (16)
- 1
CNTNAP2 in neurodevelopmental disorders: Genetics, excitation/inhibition mechanisms and preclinical evidence.
Dhungel A, Bora R, Chamidah AN, Menge DM
Molecular and cellular neurosciences 2026; (139()):104127 doi:10.1016/j.mcn.2026.104127.
PMID: 42815598 - 2
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.
Strzelczyk A, Schubert-Bast S
CNS drugs 2022; (36(10)):1079-1111 doi:10.1007/s40263-022-00955-9.
PMID: 36194365 - 3
Genotype-phenotype correlation in contactin-associated protein-like 2 (CNTNAP-2) developmental disorder.
D'Onofrio G, Accogli A, Severino M, et al.
Human genetics 2023; (142(7)):909-925 doi:10.1007/s00439-023-02552-2.
PMID: 37183190 - 4
Bilateral temporal lobe dysplasia and seizure onset associated with biallelic CNTNAP2 variants.
Panza N, Bianchini C, Cetica V, et al.
Epilepsia open 2024; (9(1)):417-423 doi:10.1002/epi4.12843.
PMID: 37805811 - 5
A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication.
Strzelczyk A, Schubert-Bast S
CNS drugs 2022; (36(3)):217-237 doi:10.1007/s40263-022-00898-1.
PMID: 35156171 - 6
Precision Medicine Approaches for Infantile-Onset Developmental and Epileptic Encephalopathies.
Myers KA, Scheffer IE
Annual review of pharmacology and toxicology 2022; (62()):641-662 doi:10.1146/annurev-pharmtox-052120-084449.
PMID: 34579535 - 7
Defining Dravet syndrome: An essential pre-requisite for precision medicine trials.
Li W, Schneider AL, Scheffer IE
Epilepsia 2021; (62(9)):2205-2217 doi:10.1111/epi.17015.
PMID: 34338318 - 8
Rates of Status Epilepticus and Sudden Unexplained Death in Epilepsy in People With Genetic Developmental and Epileptic Encephalopathies.
Donnan AM, Schneider AL, Russ-Hall S, et al.
Neurology 2023; (100(16)):e1712-e1722 doi:10.1212/WNL.0000000000207080.
PMID: 36750385 - 9
Practical consensus recommendations for polytherapy involving stiripentol in Dravet syndrome: A nominal group approach.
Cross JH, Nabbout R, Gidal B, et al.
Epilepsia open 2026; (11(3)):833-846 doi:10.1002/epi4.70245.
PMID: 41848774 - 10
Nonconvulsive status epilepticus in epileptic encephalopathies in childhood.
Hamad AP, Ferrari-Marinho T, Caboclo LO, et al.
Seizure 2020; (80()):212-220 doi:10.1016/j.seizure.2020.06.024.
PMID: 32645639 - 11
Overview of clinical and physiologic aspects of status epilepticus in the developmental and epileptic encephalopathies.
Wirrell EC
Epilepsy & behavior : E&B 2024; (159()):109950 doi:10.1016/j.yebeh.2024.109950.
PMID: 39067356 - 12
Exploring the clinical spectrum of CNTNAP2-related neurodevelopmental disorders: A case series and a literature appraisal.
Barcia G, Scorrano G, Rio M, et al.
European journal of medical genetics 2024; (72()):104979 doi:10.1016/j.ejmg.2024.104979.
PMID: 39423951 - 13
Technical Neurosurgical Aspects of Pediatric Epilepsy Surgery Including Resections and Disconnections.
Botros D, Warsi NM, Bollo RJ
Pediatric neurosurgery 2026; (61(1)):49-55 doi:10.1159/000549430.
PMID: 41231745 - 14
Add-on ketogenic diet versus antiseizure medications alone in children with developmental and epileptic encephalopathies: a prospective comparative cohort study.
Hu W, Li L, Zhao F, et al.
Frontiers in neurology 2025; (16()):1677046 doi:10.3389/fneur.2025.1677046.
PMID: 41127284 - 15
Vagus nerve stimulation for treating developmental and epileptic encephalopathy in young children.
Geng G, Hu W, Meng Y, et al.
Frontiers in neurology 2023; (14()):1191831 doi:10.3389/fneur.2023.1191831.
PMID: 37928141 - 16
Beyond seizures: proceedings of the ERN EpiCARE working group 18 on developmental and epileptic encephalopathies.
De Giorgis V, Dalla Bernardina B, Brambilla I, et al.
Epilepsy & behavior : E&B 2026; (182()):111112 doi:10.1016/j.yebeh.2026.111112.
PMID: 42161158
This page explains seizure treatment and emergency planning for CNTNAP2-related DEE for informational purposes only and does not replace medical advice. Follow your child's individualized Seizure Action Plan and contact the treating neurologist or emergency services when needed.